BLRX has been the topic of a number of other research reports. HC Wainwright set a $4.00 target price on BIOLINERX Ltd/S and gave the company a buy rating in a report on Wednesday, October 3rd. Zacks Investment Research upgraded BIOLINERX Ltd/S from a sell rating to a hold rating in a report on Wednesday. ValuEngine upgraded BIOLINERX Ltd/S from a hold rating to a buy rating in a report on Tuesday, October 16th. MED started coverage on BIOLINERX Ltd/S in a report on Wednesday, August 1st. They issued a market perform rating on the stock. Finally, Maxim Group reiterated a buy rating and issued a $2.00 target price on shares of BIOLINERX Ltd/S in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $2.50.
NASDAQ BLRX traded down $0.01 on Friday, hitting $0.70. 391,694 shares of the company were exchanged, compared to its average volume of 1,728,884. The company has a market cap of $78.77 million, a PE ratio of -2.59 and a beta of 0.87. BIOLINERX Ltd/S has a twelve month low of $0.67 and a twelve month high of $1.84.
A hedge fund recently bought a new stake in BIOLINERX Ltd/S stock. Fosun International Ltd bought a new stake in BIOLINERX Ltd/S (NASDAQ:BLRX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned 1.27% of BIOLINERX Ltd/S at the end of the most recent reporting period. Institutional investors own 34.69% of the company’s stock.
About BIOLINERX Ltd/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Featured Story: How analysts view the yield curve
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.